Compare SLGN & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLGN | INDV |
|---|---|---|
| Founded | 1987 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.4B |
| IPO Year | 1994 | 2014 |
| Metric | SLGN | INDV |
|---|---|---|
| Price | $46.14 | $40.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $52.78 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 04-29-2026 | 06-08-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | 4.65 | ★ 8100.00 |
| EPS | 0.60 | ★ 0.69 |
| Revenue | ★ $4,489,927,000.00 | $1,239,000,000.00 |
| Revenue This Year | $4.99 | N/A |
| Revenue Next Year | $2.20 | N/A |
| P/E Ratio | $75.77 | ★ $58.71 |
| Revenue Growth | 0.92 | ★ 4.29 |
| 52 Week Low | $35.68 | $16.69 |
| 52 Week High | $55.92 | $42.81 |
| Indicator | SLGN | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 60.23 | 53.87 |
| Support Level | $36.81 | $39.20 |
| Resistance Level | $47.72 | $41.42 |
| Average True Range (ATR) | 1.38 | 1.37 |
| MACD | -0.22 | -0.15 |
| Stochastic Oscillator | 54.95 | 56.03 |
Silgan Holdings Inc is a manufacturer of sustainable rigid packaging solutions for the world's essential consumer goods products. Its products include: dispensing and specialty closures for fragrance and beauty, food, beverage, personal and health care, home care and lawn and garden products; steel and aluminum containers for pet and human food and general line products; and custom designed plastic containers for pet and human food, consumer health and pharmaceutical, personal care, home care, lawn and garden and automotive products.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).